tetano
Editor, Senior Moderator
Cureus
. 2021 Jul 30;13(7):e16746.
doi: 10.7759/cureus.16746. eCollection 2021 Jul.
Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
Natalia Lattanzio[SUP] 1 [/SUP], Cristina Acosta-Diaz[SUP] 1 [/SUP], Ricardo J Villasmil[SUP] 1 [/SUP], Zachary Kirkland[SUP] 1 [/SUP], Caitlin Bass[SUP] 2 [/SUP], Sage Yenari[SUP] 3 [/SUP], Jorge Conte[SUP] 1 [/SUP], Kevin Dawkins[SUP] 1 [/SUP], Tamela Fonseca[SUP] 4 [/SUP], Cindy Grimes[SUP] 2 [/SUP], Angie Stewart[SUP] 5 [/SUP], Mary E Geary[SUP] 6 [/SUP], Harold Vore[SUP] 7 [/SUP], Karen Hamad[SUP] 1 [/SUP], Wilhelmine Wiese-Rometsch[SUP] 1 [/SUP], James Fiorica[SUP] 8 [/SUP], Manuel Gordillo[SUP] 9 [/SUP], Roberto Mercado[SUP] 9 [/SUP], Kirk Voelker[SUP] 10 [/SUP]
Affiliations
Abstract
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.
Keywords: convalescent plasma; covid-19; discharge to home; infusion; sars-cov-2.
. 2021 Jul 30;13(7):e16746.
doi: 10.7759/cureus.16746. eCollection 2021 Jul.
Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
Natalia Lattanzio[SUP] 1 [/SUP], Cristina Acosta-Diaz[SUP] 1 [/SUP], Ricardo J Villasmil[SUP] 1 [/SUP], Zachary Kirkland[SUP] 1 [/SUP], Caitlin Bass[SUP] 2 [/SUP], Sage Yenari[SUP] 3 [/SUP], Jorge Conte[SUP] 1 [/SUP], Kevin Dawkins[SUP] 1 [/SUP], Tamela Fonseca[SUP] 4 [/SUP], Cindy Grimes[SUP] 2 [/SUP], Angie Stewart[SUP] 5 [/SUP], Mary E Geary[SUP] 6 [/SUP], Harold Vore[SUP] 7 [/SUP], Karen Hamad[SUP] 1 [/SUP], Wilhelmine Wiese-Rometsch[SUP] 1 [/SUP], James Fiorica[SUP] 8 [/SUP], Manuel Gordillo[SUP] 9 [/SUP], Roberto Mercado[SUP] 9 [/SUP], Kirk Voelker[SUP] 10 [/SUP]
Affiliations
- PMID: 34513370
- PMCID: PMC8405359
- DOI: 10.7759/cureus.16746
Abstract
On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.
Keywords: convalescent plasma; covid-19; discharge to home; infusion; sars-cov-2.